HIV New Product Introduction Toolkit

This tool was developed to support national HIV programs and ministries of health to estimate and compare the cost of the following two...

The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for an HIV/AIDS treatment...

The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....

The purpose of this guidance from EGPAF is to aid health care workers and support caregivers and children initiated on, or switched to,...

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

This guidance from EGPAF is intended for national program managers; technical and clinical advisors; procurement entities; funding...

CHAI has developed new resources to support healthcare worker decision-making and counselling around pDTG. pDTG HCW Worker Overview Video...

Fillable report and presentation template for governments to adjust as needed for introduction of pediatric DTG. English | French

Optimal and FASTER CAB members, with technical support from CHAI, developed a multi-media package of treatment literacy and advocacy...

This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for...

A CHAI-curated repository of clinical studies in the development and implementation of pediatric DTG.

This memo highlights the patient benefits, cost savings and improved supply security associated with proactively switching eligible 2L...

CHAI's TLD resources help countries in creating the best plan for TLD introduction. CHAI TLD Clinical Action Memo CHAI DTG Use In Women...